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Hypovitaminosis D and secondary hyperparathyroidism are frequent among HIV-infected patients. As there are no data about
the best supplementation therapy both in treatment and in maintenance, we conducted an observational study of 300 HIV-
infected patients for whom vitamin D and parathormone (PTH) had been measured in order to validate a protocol of vitamin D
supplementation in patients withHIV-infection. Patients with vitaminDdeficiency (defined as 25(OH)D< 10 ng/mL), insufficiency
(defined as 25(OH)D < 20 ng/mL), or hyperparathyroidism (PTH > 65 pg/mL) were supplemented with cholecalciferol 16.000IU
(0.266mg) weekly (if deficiency) or fortnightly (if insufficiency or high PTH levels). Rates of normalization of 25(OH)D (levels
above 20 ng/mL) and PTH levels (<65 pg/mL) were analyzed. Multivariate analysis of factors related to normalization was carried
out. With a median follow-up of 2 years, 82.1% of patients with deficiency and 83.9% of cases with insufficiency reached levels
above 20 ng/mL. However, only 67.2% of individuals with hyperparathyroidism at baseline reached target levels (<65 pg/mL).
Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use. In HIV-infected patients
with hypovitaminosis, the protocol of cholecalciferol supplementation normalized vitamin D levels regardless of antiretroviral
regimen in a high proportion of patients but it was less effective to correct hyperparathyroidism.
1. Introduction
In recent years, a growing number of studies have reported
high prevalence rates of vitamin D deficiency among HIV-
infected patients [1]. The prevalence of hypovitaminosis goes
from 42 to 95% in different studies [2–4]. In a previous study
conducted in our hospital hypovitaminosis was reported in as
many as 71.2% of HIV-infected patients (39.6% of them were
vitamin D deficient as defined by levels below 10 ng/mL) [5].
The relevance of the high prevalence of hypovitaminosis
D among HIV patients is that vitamin D is not only a well-
established factor for bone disease [6–11], but also associ-
ated with nonskeletal conditions, including cardiovascular,
immune regulation, cancer, and neurocognitive disorders
[12–14]. Moreover, some studies suggest that severe vitamin
D deficiency is associated with HIV progression, mortality,
and AIDS events [2].
Risk factors for hypovitaminosis D are female sex, dark
skin pigmentation, low dietary intake, seasonality, insuf-
ficient sun exposure, and high body mass index [15–19].
Recently we also identified as predictors of vitamin D defi-
ciency in HIV-infected patients the existence of psychiatric
comorbidity while lipoatrophy was a protective factor [5].
In addition to all classic risk factors, these subjects are also
exposed to HIV-related factors associated with vitamin D
deficiency such as immune activation, chronic inflammation,
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and viral and antiretroviral treatment with potential interac-
tions on the vitamin D metabolism [20–26].
The systematic screening for vitamin D deficiency is
controversial. The most recent EACS guidelines [27] suggest
screening for hypovitaminosis D for every HIV-positive
subject having a bone disease (low bone mineral density,
previous fractures, or high risk for fractures) or other known
factors for vitamin D deficiency. Vitamin D repletion is
recommended when 25(OH)D levels are below 10 ng/mL.
Furthermore it may be indicated in presence of vitamin D
values between 10 and 30 ng/mL if associated with bone
disease or secondary hyperparathyroidism. Elevated levels of
PTH as a consequence of chronic vitamin D deficiency have
been linked to bone loss [28]. Accordingly, EACS guidelines
recommend vitaminD supplementation to reach levels above
20 ng/mL and normalizing serum PTH levels [27].
Arguments against the widespread screening for vitamin
D deficiency in HIV-infected patients include the unclear
benefit of vitamin D replacement for nonmusculoskeletal
outcomes, the cost of laboratory testing and treatment, and
the potential toxicities of some supplementation approaches
[29]. Furthermore, the optimal repletion and maintenance
dosing regimens remain to be established as well as the
impact of vitamin D supplementation in preventing comor-
bidities [1]. Another study proposed that a dose of 16.000 IU
calcidiol monthly during 9 months [30] was efficacy in
decreasing the prevalence of hypovitaminosis D and the rates
of associated hyperparathyroidism.
Therefore, accepting the evidence that adequate vitamin
D levels are beneficial for HIV patients we implemented a
protocol for vitamin D supplementation and analyzed the
factors influencing the achievement of these target levels
in a clinical population where a protocol for vitamin D
supplementation has been implemented. Moreover, we also
analyzed the relationship between vitamin D and PTH levels.
2. Materials and Methods
2.1. Patients and Study Design. An observational study was
conducted at the Department of Infectious Diseases at Hos-
pital del Mar (Barcelona, Spain), analyzing 300 HIV-infected
out-patients who were naı¨ve or on stable HAART (highly
active antiretroviral therapy) for whom vitamin D levels had
been measured (fasting status). Patients were followed up in
our department and visited between June 2010 and October
2013. The study was approved by the hospital ethical com-
mittee and all subjects provided written informed consent.
All patients' data were anonymized for data management and
statistical analysis. As an observational study, there was no
control arm for comparison and hence no randomization.
2.2. Quantification of Laboratory Values. Vitamin D (com-
petitive electrochemiluminescence protein binding assay,
Cobas e602.Roche Diagnostics, Germany) status was cate-
gorized as insufficient when <20 ng/mL and deficient when
<10 ng/mL and hyperparathyroidism as PTH levels (solid-
phase, two-site chemiluminescent enzyme-labeled immuno-
metric assay; IMMULITE 2000, Siemens; Los Angeles, CA,
USA) >65 pg/mL. Secondary laboratory variables included
serum levels of calcium (8.5–10.5mg/dL), phosphate (2.5–
4.8mg/dL), alkaline phosphatase (40–129 IU/L), CD4 and
CD8 lymphocytes counts, and HIV viral load (COBAS,
AmpliPrep/TaqMan HIV-1 test, Roche Diagnostics).
The following demographic and clinical data were
assessed: gender, age, race, risk factors for HIV-infection,
HAART, and hepatitis C and B coinfection. For the analysis
were excluded patients with renal insufficiency (defined
as glomerular rate filtration <60mL/min, estimated using
Modification of Diet in Renal Disease (MDRD) equation),
hepatic insufficiency (defined asChild Pugh stageC), patients
under chemotherapy, and those already receiving vitamin D,
bisphosphonates, and calcium supplements (and the other
classical exclusion criteria).
Subjects were supplemented with 16.000 IU or 0.266mg
of vitamin D3 (cholecalciferol, Hidroferol, FAES FARMA)
weekly, fortnightly, or monthly according to vitamin D base-
line and PTH concentrations and according to the supple-
mentation protocol designed by theDepartment of Infectious
Diseases at Hospital del Mar (Figure 1). Those patients with
vitaminDbelow 10 ng/mLwere supplementedwith 16.000 IU
of cholecalciferol weekly. Patients with vitamin D above
10 ng/mL were replaced according to PTH values, though for
those with PTH > 70 ng/mL 1 dose fortnightly was used and
those with PTH < 65 ng/mL did not receive supplements.
All subjects were reevaluated after 4–6 months and at every
outpatient visit thereafter up to two years of follow-up.
If vitamin D levels reached levels between 30 ng/mL and
100 ng/mL, the dose was modified to 16.000 IU fortnightly.
When serum vitamin D reached levels above 100 ng/mL the
dosage was modified to 16.000 IU every month. During the
follow-up all patients were reevaluated 3 times. Subjects with
normal vitamin D levels were not supplemented. Vitamin D
toxicity was defined as concentrations above 150 ng/mL [31].
2.3. Statistical Analysis. Univariate analyses were performed
with chi-square test and ORs and its 95% confidence interval
was estimated by logistic regression.
Data of 300 participants from the 3 follow-up moments
were pooled resulting in 798 registers.With the data arranged
in this manner a LinearMixedModel was performed to anal-
yse the relationship between PTH and vitamin D, adjusted
by TDF. In this model the individual (the identifier) was
included as a random effect.
To analyse the factors associated to achieve the objective
of 25(OH)D level above 20 ng/mL and PTH level below
65 pg/mL a chi-square analysis was done for the univariate
analysis and a logistic regression model for the multivariate
analysis; both analyses were done in patients with baseline
25(OH)D < 20 ng/mL and baseline 25(OH)D < 10 ng/mL.
Statistical analysis was performed with R Statistical
Package (R Foundation for Statistical Computing, Vienna,
Austria; Version 2.15.1).
3. Results
3.1. Study Population. The characteristics of the 300 patients
included in the study are presented in Table 1. The median
AIDS Research and Treatment 3
Vitamin D
Cholecalciferol PTH
Cholecalciferol No supplementation Vitamin D
Cholecalciferol Cholecalciferol 
16.000 IU/15 days
16.000 IU monthly
>100ng/mL>30ng/mL
<65pg/mL>70pg/mL
16.000 IU weekly
<10ng/mL >10ng/mL
16.000 IU/15 days
Figure 1: Protocol of vitamin D supplementation.
Table 1: Demographic and clinical characteristics of the study
population.
Age (years) Mean (SD): 46.96 (9.61)
Median range: 46 (41–52)
Sex 𝑛 (%) Male: 219 (73)
Female: 81 (27)
Ethnic background 𝑛 (%)
White: 253 (84.3)
Hispanic: 27 (9)
Black: 9 (3)
Risk group 𝑛 (%)
IDU: 110 (36.7)
MSM: 106 (35.3)
Heterosexual: 74 (24.7)
Others: 7 (3.3)
HAART 𝑛 (%)
Yes: 283 (95.3)
No: 17 (4.7)
NNRTI: 130 (43.3)
PI: 165 (55)
TDF: 173 (57.5)
ABC: 63 (21)
Serum 25(OH)D category 𝑛 (%)
<10 ng/mL: 84 (28)
<20 ng/mL: 186 (62)
>20 ng/mL: 114 (38)
PTH > 65 pg/mL 𝑛 (%) Yes: 137 (45.7)
No: 163 (54.3)
age of participants was 46 years (range 41–52), 219 (73%) were
males, and 253 (84.3%) were caucasians. Predominant risk
groups for HIV-transmission were IDU (intravenous drug
users) (36.7%) andMSM (men having sex withmen) (35.3%).
At the time of sampling 283 patients (95.3%) were on cART;
from those 173 (57.7%) were exposed to TDF, 130 (43.3%) to
nonnucleoside reverse transcriptase inhibitors (NNRTI), and
173 (55%) to ritonavir-boosted protease inhibitor regimen
(PI). The proportions of vitamin D deficiency and insuffi-
ciency were 28% and 62%, respectively, and 45.7% of the
patients had secondary hyperparathyroidism.
The protocol described in Figure 1 was intended to be
applied in the 300 HIV-infected patients.
3.2. Changes in Vitamin D and PTH. At baseline, 84 patients
were vitamin D deficient and 186 insufficient. All patients,
both deficient and insufficient, were offered supplementation
but all those who declined this option were not supple-
mented. A total amount of 22 patients of those with vitamin
D deficiency and 58 of those with insufficiency declined
supplementation.
62 patients with vitamin D deficiency (73.8%) were
supplemented (Table 2). After completing 24 months, 2
(3.2%) participants receiving vitamin D had a trough serum
25(OH)D concentration <20 ng/mL compared to 13 (59.1%)
of those not supplemented (𝑝 < 0.0001). Vitamin D objective
was influenced by neither TDF exposure (𝑝: 0.65) nor non-
nucleoside exposure (𝑝: 0.23). A high proportion of patients
on PI therapy achieved 25(OH)D concentration >20 ng/mL
(89.4% versus 73%; 𝑝: 0.08); however, the difference did not
reach statistical significance. At the multivariate analysis, the
only significant factor associated with achieving the objective
of 25(OH)D concentration >20 ng/mL was cholecalciferol
supplementation (𝑝 < 0.0001).
Table 3 shows the factors associated with PTH objective
(PTH < 65 pg/mL) in patients with vitamin D deficiency.
VitaminD supplements had no effect over PTHobjective, but
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Table 2: Patients with vitamin D < 10 ng/mL at baseline. Objective vitamin D > 20 ng/mL. Univariate and multivariate analysis.
Univariate analysis Multivariate analysis
Objective yes:
69 (82.1%)
𝑛 (%)
Objective no:
15 (17.9%)
𝑛 (%)
𝑝 OR (95% CI) 𝑝
VitD supplements
Yes 60 (96.8) 2 (3.2) 0.0001 66.76 (10.06–442.85) 0.0001
No 9 (40.9) 13 (59.1)
TDF exposure 0.33 (0.05–1.92) 0.22
Yes 32 (84.2) 6 (15.8) 0.65
No 37 (80.4) 9 (19.6)
NNRTI exposure 1.12 (0.69–18.38) 0.93
Yes 26 (76.5) 8 (23.5) 0.26
No 43 (86) 7 (14)
PIs exposure 0.19 (0.01–2.97) 0.23
Yes 42 (89.4) 5 (10.6) 0.08
No 27 (73) 10 (27)
Table 3: Linear Mixed Model, PTH dependent variable.
Slope 95% CI
Variable Slope Lower Upper Correlation 𝑝 value
VitD −0.213 −0.291 −0.134 −0.592 <0.001
TDF 10.643 4.861 16.425 — <0.001
at the logistic regression tenofovir exposure was a risk factor
associated with not achieving PTH objective (OR: 3.77 (1.36–
10.43)).
The results were similar in those subjects with vitamin
D insufficiency. The proportion of participants with vitamin
D <20 ng/mL was 62% (186 patients) of whom 128 subjects
were supplemented with cholecalciferol. More patients in
the supplemented regimen achieved vitaminD concentration
>20 ng/mL after treatment than those not supplemented
(95.5% compared with 53.8%, resp.; 𝑝 = 0.0001). Table 4
summarizes the factors associated with reaching both objec-
tives, vitamin D and PTH. As in the patients with vitamin D
deficiency, PI based therapies and those with TDF exposure
were associated with a higher risk of not achieving PTH levels
under 65 pg/mL.
Although cholecalciferol supplementation did not seem
to correct the secondary hyperparathyroidism in the qual-
itative analysis it had an effect over PTH concentration
so for each increasing unit of vitamin D, PTH decreased
0.213 pg/mL (𝑝 < 0.001). Moreover, PTH values were signifi-
cantly higher, 10.643 pg/mL, in those patients exposed to TDF
(𝑝 < 0.001) (Table 5).
No changes on HAART due to vitamin D for PTH levels
were made. Those HAART switches during supplementation
were made for either virologic failure or adverse events
related to antiretroviral therapy.
Therewere no differences between patients supplemented
and those not with respect to the frequencies of possi-
ble adverse events including infectious diseases, fractures,
cancer, and cardiovascular diseases, so we considered there
were no events attributable to vitaminD replacement. During
the course of the study no patient in replacement group
presented toxicities (no hypercalcemia).Themean viral load,
CD4 number and CD4%, calcium, phosphate, and alkaline
phosphatase measurements did not differ between baseline
and the end of the study.
4. Discussion
Considering that hypovitaminosis is associated with unfa-
vorable outcomes of some chronic infections such as HIV
[32] and the increasing evidence of its role in innate and cell
mediated immunity [33] we proposed a practical scheme for
vitamin D supplementation. When designing this protocol
we focused on several problems. First of all, the recent devel-
opment of the once-daily single tablet regimen has optimized
HAART regimens and improved long term adherence, as
well as quality of life [34]. But HAART has also increased
life expectancy and therefore age-related morbidities as well
as the need for concomitant medication. In a recent study,
suboptimal adherence was associatedwith greater pill burden
and higher maximum number of doses per day [35]. The
aim of the proposed scheme was the avoidance of adherence
problems; thus we designed a protocol in which we could give
the least possible number of doses: maximum 1 per week and
at least 1 monthly. On the other hand recommendations on
screening and vitamin D supplementation remain sparse and
controversial and the target level of vitamin D to be reached
after replacement is not yet known. Some investigators
consider that aminimum serum concentration of 30 ng/mL is
necessary, whereas others suggest that the calciotropic func-
tions of vitamin D are enhanced with higher concentrations
of serum 25(OH)D within the current reference range [36–
39].
The results of this study demonstrate that supplemen-
tation of HIV-infected individuals with vitamin D is well
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Table 4: Patients with vitamin D < 10 ng/mL at baseline. Objective PTH < 65 pg/mL.
Univariate analysis Multivariate analysis
Objective yes
56 (66.7) OR (95% CI) 𝑝 OR (95% CI) 𝑝
VitD supplements
Yes 41 (66.1) 0.91 (0.32–2.85) 0.86 1.05 (0.34–3.24) 0.92
No 15 (68.2)
TDF exposure
Yes 20 (52.6) 3.24 (1.26–8.35) 0.01 3.77 (1.36–10.43) 0.01
No 36 (78.3)
NNRTI exposure
Yes 23 (67.3) 1.08 (0.43–2.72) 0.87 3.36 (0.55–20.50) 0.19
No 33 (66)
PIs exposure
Yes 28 (59.6) 2.11 (0.82–5.46) 0.12 7.04 (1.09–45.47) 0.04
No 28 (75.7)
Table 5: Analysis patients with vitamin D < 20 ng/mL at baseline.
Objective
VitD > 20 ng/mL
Yes: 156 (83.9)
𝑛 (%)
𝑝
Objective:
PTH < 65 pg/mL 𝑝
VitD supplements
Yes 128 (95.5) 0.0001 90 (67.2) 0.43
No 28 (53.8) 39 (73.1)
TDF exposure
Yes 80 (89.9) 0.03 54 (60.7) 0.02
No 76 (78.4) 74 (76.3)
NNRTI exposure
Yes 75 (85.5) 0.58 61 (73.5) 0.22
No 76 (82.5) 67 (65)
PIs exposure
Yes 83 (84.7) 0.75 61 (62.2) 0.04
No 73 (83) 67 (76.1)
tolerated, safe, and effective, as more than 95% of the patients
achieved vitaminD levels above 20 ng/mL, with the proposed
schedule of administration.
In the current study, as in others, supplementation did
not significantly affect calcium, phosphorus, and alkaline
phosphatase during the period of observation. In addition,
no differences were observed in the mean viral load, CD4
number, and CD4% between baseline and the end of the
study. Moreover, in contrast to other studies, neither baseline
concentration of vitamin D nor vitamin objectives were
influenced by the cART use [20, 22, 40].
On the other hand, PTH elevation plays a direct role over
bone disease among HIV-infected patients, as it acts on bone
to release calcium and persistent PTH elevations are associ-
ated with bone loss across a range of clinical conditions [41–
43]. Studies on evaluation of secondary hyperparathyroidism
in HIV-infected patients are scarce; as a result there are
few data on the impact of this condition on the health of
individuals [44].
Because low vitamin D was associated with PTH
increases, we hypothesized that vitamin D repletion may
reduce the risk of PTH abnormalities. Many studies have
shown that serum PTH is inversely related to serum
25(OH)D, and thatwith the increase in serum25(OH)D there
is a decrease in serum PTH that usually reaches a plateau.
In the Endocrine Society guidelines [45], the statement is
made that serum PTH reaches a plateau at a threshold of
30 ng/mL, but this is supported by only a few references,
since in recent literature there is a large variability in the
reported level of serum vitamin D at which PTH reached a
plateau or was maximally suppressed [46]. In our study, as
in others before, serum PTH was inversely correlated with
serum 25(OH)D but no threshold as defined by suppression
of serumPTHwas found. Sai et al. showed similar results, but
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they do found a threshold for bone markers that increased
only below a vitamin D of approximately 18 ng/mL, so they
conclude that vitamin D insufficiency should be defined as
25(OH)D <20 ng/mL as it relates to bone. Although there is
not much literature about PTH normalization, we report that
66.7% of the patients achieve PTH levels <65 pg/mL after 2-
year follow-up. We hypothesized that a longer follow-up may
increase the number of patients that correct hyperparathy-
roidism because after supplementation the time it takes to
normalize PTH is not set.
In different studies vitamin D has been associated with
TDF-linked hyperparathyroidism emphasizing that both,
TDF use and vitamin D status, influence in PTH values.
Although the mechanism by which TDF produces hyper-
parathyroidism is unclear, a previous study suggests that
the increased hydroxylation rates and tubular phosphate
losses, which drive calcium preservation and possibly altered
bone metabolism, are dependent on vitamin D status [47].
Moreover PTH elevations have been observed in patients
taking bothNNRT and PI [48–50].We observed that patients
under TDF treatment presented PTH values significantly
higher which is consistent with other studies [51]. Although
vitamin D treatment may decrease PTH in persons taking
TDF in the absence of measurable vitamin D deficiency, in
our study TDF or IP exposure was a risk factor for not
achieving PTH objective. So it is suggested that because
1,25(OH)D directly decreases PTH and vitamin D treatment
increases 1,25(OH)D and its direct effect may decrease PTH.
But as hyperparathyroidism may be multifactorial in HIV-
infected patients and TDF may have effects on other factors
that directly increase PTH, vitaminD supplementation could
be not enough to normalize PTH but to improve the levels as
we have seen in the present study.
Limitations of the present study are mainly related to
the observational design nature of the current analyses. In
this respect, the results reported herein are only associations
fromwhich no conclusions regarding causality can be drawn.
The 25(OH)D measurements were done along the whole
year, independently of seasonality. On the other hand we did
not examine sun exposure, nor intakes of dietary calcium,
although dietary calcium deficiency is rare in our population
due to Mediterranean diet, and serum calcium and phos-
phorus were normal during the complete follow-up. Calcium
urinary excretion was not measured.
In conclusion we demonstrate that the proposed scheme
for vitamin D supplementation in HIV-infected patients is
safe and valid for correcting vitamin D abnormalities and to
improve raised PTH levels, but not enough for normalizing
them, especially in patients exposed to tenofovir or protease
inhibitors.
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